Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

North American Intrauterine Contraceptive Devices (IUCD) Market by Type (Hormonal IUCD, Copper IUCD): Global Opportunity Analysis and Industry Forecast, 2023-2032

A00660

Pages: NA

Charts: NA

Tables: NA

Intrauterine contraceptive device (IUCD) is a reversible, long acting T-shaped device, which is inserted into uterus for contraception purposes. It prevents fertilization of eggs in the uterus and thus, helps to avoid pregnancy. IUCDs can provide contraception for 3 to12 years after insertion into the vagina, depending on type of ICUD and preference. IUCDs do not interfere in sexual intercourse or breastfeeding and can be used as an effective alternative to contraceptive pills. It can be inserted immediately after delivery or abortion. Women are able to retain fertility rapidly after its removal. IUCDs are widely used due to lower failure rates and cost effective nature for long-term use.

The major driving factors of the North American intrauterine contraceptive devices market are the increasing rate of unplanned pregnancies, especially in young females and the rising need for controlling population growth. Similarly, IUCD provides several advantages such as fewer side effects over oral contraception, which is a major driving factor. In addition, favorable government initiatives would further provide boost to the market. For instance, the implementation of the Affordable Care Act (ACA), supportive private firms initiatives for reducing expenses related to abortion, and funds for IUCD products have augmented the market growth. However, high rate of complications during unplanned pregnancy, high costs of treatment, threat of ectopic pregnancy, and the need for compulsory assistance of medical professionals are factors hindering the growth of the market. Despite several restrain, the increasing number of manufacturers and technological advancements would create huge growth opportunities for the North America intrauterine contraceptive devices market in near future.
The North American intrauterine contraceptive devices market is segmented on the basis of type, into hormonal IUCD and copper IUCD. Geographic breakdown and deep analysis of each of the aforesaid segments is included for United States., Canada, and Mexico.

The report provides, comprehensive competitive analysis and profiles of major market players such as Bayer Healthcare AG, Teva Pharmaceutical Industries Ltd., Actavis PLC, Medicines360, Trimedic Supply Network Ltd., Medisafe Distribution Inc., and Pace Pharmaceuticals Inc. have been provided in this report. The leading market players have adopted mergers & acquisitions and partnerships as one of the key developmental strategy., in order to gain strong foothold of market.

KEY BENEFITS FOR STAKEHOLDERS:

  • The report offers a detailed analysis of key driving and restraining factors of the North American intrauterine contraceptive devices market.
  • The report provides an extensive analysis of current and future market status of the North American intrauterine contraceptive devices market.
  • This report offers an in-depth quantitative analysis of the current market and estimations through 2015-2020, which assists in identifying the prevailing market opportunities.
  • An extensive analysis of dominant market shares for each segment helps in understanding the current status of market.
  • The report provides an exhaustive information about new product launches, research and recent developments of the North American intrauterine contraceptive devices market.
  • An in-depth analysis of key strategies adopted by major companies helps in understanding competitive scenario.
  • SWOT analysis highlights the internal environment of the leading companies for effective strategy formulation.

KEY MARKET SEGMENTS:

  • By Type
    • Hormonal IUCD
    • Copper IUCD
  • By Geography
    • United States
    • Canada
    • Mexico

Key Market Segments

  • By Type
    • Hormonal IUCD
    • Copper IUCD
  • By Geography
    • United States
    • Canada
    • Mexico


Key Market Players

  • Allergan plc
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • CooperSurgical, Inc.
  • HLL Lifecare Limited
  • EMD Serono, Inc.
  • Pfizer Inc.
  • Evofem Biosciences, Inc.
  • Merck & Co., Inc.
  • PMI Reproductive Health, Inc.
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Hormonal IUCD

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Copper IUCD

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Type

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S.

        • 5.2.4.1 Market size and forecast, type

      • 5.2.5. Canada

        • 5.2.5.1 Market size and forecast, type

      • 5.2.6. Mexico

        • 5.2.6.1 Market size and forecast, type

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Type

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France

        • 5.3.4.1 Market size and forecast, type

      • 5.3.5. Germany

        • 5.3.5.1 Market size and forecast, type

      • 5.3.6. Italy

        • 5.3.6.1 Market size and forecast, type

      • 5.3.7. Spain

        • 5.3.7.1 Market size and forecast, type

      • 5.3.8. UK

        • 5.3.8.1 Market size and forecast, type

      • 5.3.9. Russia

        • 5.3.9.1 Market size and forecast, type

      • 5.3.10. Rest Of Europe

        • 5.3.10.1 Market size and forecast, type

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Type

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China

        • 5.4.4.1 Market size and forecast, type

      • 5.4.5. Japan

        • 5.4.5.1 Market size and forecast, type

      • 5.4.6. India

        • 5.4.6.1 Market size and forecast, type

      • 5.4.7. South Korea

        • 5.4.7.1 Market size and forecast, type

      • 5.4.8. Australia

        • 5.4.8.1 Market size and forecast, type

      • 5.4.9. Thailand

        • 5.4.9.1 Market size and forecast, type

      • 5.4.10. Malaysia

        • 5.4.10.1 Market size and forecast, type

      • 5.4.11. Indonesia

        • 5.4.11.1 Market size and forecast, type

      • 5.4.12. Rest of Asia Pacific

        • 5.4.12.1 Market size and forecast, type

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Type

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil

        • 5.5.4.1 Market size and forecast, type

      • 5.5.5. South Africa

        • 5.5.5.1 Market size and forecast, type

      • 5.5.6. Saudi Arabia

        • 5.5.6.1 Market size and forecast, type

      • 5.5.7. UAE

        • 5.5.7.1 Market size and forecast, type

      • 5.5.8. Argentina

        • 5.5.8.1 Market size and forecast, type

      • 5.5.9. Rest of LAMEA

        • 5.5.9.1 Market size and forecast, type

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning,2022

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Pfizer Inc.

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Teva Pharmaceutical Industries Ltd.

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Bayer AG

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Merck And Co., Inc.

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. CooperSurgical, Inc.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Evofem Biosciences, Inc.

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. HLL Lifecare Limited

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. EMD Serono, Inc.

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Allergan Plc

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. PMI Reproductive Health, Inc.

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET FOR HORMONAL IUCD, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET FOR COPPER IUCD, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. NORTH AMERICA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 6. NORTH AMERICA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 7. U.S. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 8. CANADA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 9. MEXICO NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 10. EUROPE NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 11. EUROPE NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 12. FRANCE NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 13. GERMANY NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. ITALY NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. SPAIN NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 16. UK NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. RUSSIA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. REST OF EUROPE NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. ASIA-PACIFIC NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. ASIA-PACIFIC NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. CHINA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. JAPAN NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. INDIA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. SOUTH KOREA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. AUSTRALIA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. THAILAND NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MALAYSIA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. INDONESIA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. REST OF ASIA PACIFIC NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. LAMEA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. LAMEA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. BRAZIL NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. SOUTH AFRICA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. SAUDI ARABIA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. UAE NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. ARGENTINA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. REST OF LAMEA NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD), BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. PFIZER INC.: KEY EXECUTIVES
  • TABLE 39. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 40. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 41. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 42. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 43. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 44. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 45. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 48. BAYER AG: KEY EXECUTIVES
  • TABLE 49. BAYER AG: COMPANY SNAPSHOT
  • TABLE 50. BAYER AG: OPERATING SEGMENTS
  • TABLE 51. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 52. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 53. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 54. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 55. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 56. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 57. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 58. COOPERSURGICAL, INC.: KEY EXECUTIVES
  • TABLE 59. COOPERSURGICAL, INC.: COMPANY SNAPSHOT
  • TABLE 60. COOPERSURGICAL, INC.: OPERATING SEGMENTS
  • TABLE 61. COOPERSURGICAL, INC.: PRODUCT PORTFOLIO
  • TABLE 62. COOPERSURGICAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 63. EVOFEM BIOSCIENCES, INC.: KEY EXECUTIVES
  • TABLE 64. EVOFEM BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 65. EVOFEM BIOSCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 66. EVOFEM BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 67. EVOFEM BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 68. HLL LIFECARE LIMITED: KEY EXECUTIVES
  • TABLE 69. HLL LIFECARE LIMITED: COMPANY SNAPSHOT
  • TABLE 70. HLL LIFECARE LIMITED: OPERATING SEGMENTS
  • TABLE 71. HLL LIFECARE LIMITED: PRODUCT PORTFOLIO
  • TABLE 72. HLL LIFECARE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 73. EMD SERONO, INC.: KEY EXECUTIVES
  • TABLE 74. EMD SERONO, INC.: COMPANY SNAPSHOT
  • TABLE 75. EMD SERONO, INC.: OPERATING SEGMENTS
  • TABLE 76. EMD SERONO, INC.: PRODUCT PORTFOLIO
  • TABLE 77. EMD SERONO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. ALLERGAN PLC: KEY EXECUTIVES
  • TABLE 79. ALLERGAN PLC: COMPANY SNAPSHOT
  • TABLE 80. ALLERGAN PLC: OPERATING SEGMENTS
  • TABLE 81. ALLERGAN PLC: PRODUCT PORTFOLIO
  • TABLE 82. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. PMI REPRODUCTIVE HEALTH, INC.: KEY EXECUTIVES
  • TABLE 84. PMI REPRODUCTIVE HEALTH, INC.: COMPANY SNAPSHOT
  • TABLE 85. PMI REPRODUCTIVE HEALTH, INC.: OPERATING SEGMENTS
  • TABLE 86. PMI REPRODUCTIVE HEALTH, INC.: PRODUCT PORTFOLIO
  • TABLE 87. PMI REPRODUCTIVE HEALTH, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET
  • FIGURE 3. SEGMENTATION NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET
  • FIGURE 11. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET SEGMENTATION, BY TYPE
  • FIGURE 12. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET FOR HORMONAL IUCD, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET FOR COPPER IUCD, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 18. COMPETITIVE DASHBOARD
  • FIGURE 19. COMPETITIVE HEATMAP: NORTH AMERICAN INTRAUTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET
  • FIGURE 20. TOP PLAYER POSITIONING,2022
  • FIGURE 21. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 22. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 23. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 24. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 25. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 26. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 27. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. COOPERSURGICAL, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. COOPERSURGICAL, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. COOPERSURGICAL, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. EVOFEM BIOSCIENCES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. EVOFEM BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. EVOFEM BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. HLL LIFECARE LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. HLL LIFECARE LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. HLL LIFECARE LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. EMD SERONO, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. EMD SERONO, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. EMD SERONO, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. ALLERGAN PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ALLERGAN PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. ALLERGAN PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. PMI REPRODUCTIVE HEALTH, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. PMI REPRODUCTIVE HEALTH, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. PMI REPRODUCTIVE HEALTH, INC.: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
North American Intrauterine Contraceptive Devices (IUCD) Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue